Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2020 | The MCL complete project: nationwide data collection

Mats Jerkeman • 4 Dec 2020
ASH 2020
Lymphoma Mantle Cell Lymphoma

Mats Jerkeman, MD, PhD, Skane University Hospital, Lund, Sweden, discusses the mantle cell lymphoma (MCL) Complete project, an initiative which aims to collaborate population-based data from the Swedish lymphoma register with patient records, data from first-line treatments, histopathology, and co-morbidity data to have a complete database on MCL in Sweden. At ASH 2020, overall survival (OS) and progression-free survival (PFS) data with first-line treatment and successive lines of therapy on patients with MCL were presented. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research support: Janssen, Celgene, Abbvie, Roche, Gilead
Honoraria: Celgene, Gilead, Roche, Incyte

More from Mats Jerkeman

Venetoclax, lenalidomide and rituximab in R/R MCL
2:22
Venetoclax, lenalidomide and rituximab in R/R MCL
Mats Jerkeman • 4 Dec 2020
PHILEMON trial: ibrutinib, lenalidomide and rituximab in R/R MCL
1:46
PHILEMON trial: ibrutinib, lenalidomide and rituximab in R/R MCL
Mats Jerkeman • 4 Dec 2020

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals